FDA Approves Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray for the Treatment of Patients with Chronic Obstructive Pulmonary Disease
Links shared publicly online about this topic.
- 0total visits
FDA Approves Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray for the Treatment of Patients with Chronic Obstructive Pulmonary Disease
Combivent Respimat (albuterol and ipratropium bromide) is used to treat chronic obstructive pulmonary disease. Includes Combivent Respimat side effects, interactions and indications.
View full resource at drugs.com
Tags: COPD, COPD Medication, FDA, Combivent, Proventil, Atrovent, Pulmonology
Most Recently Shared on October 11, 2011 at 12:07 am By:
FDA Approves Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray for COPD - http://t.co/3UJWkUpF
Combivent Respimat Inhalation Spray Approved for COPD - MPR
empr.com — “Boehringer Ingelheim announced that the FDA has approved Combivent Respimat (ipratropium bromide and albuterol), a propellant-free metered dose inhalation spray that uses a slow-moving mist, for the treatment of chronic obstructive pulmonary disease (COPD).” View full resource at empr.com
Most Recently Shared on October 10, 2011 at 3:15 pm By:
Combivent Respimat Inhalation Spray Approved for #COPD http://ow.ly/6SDtO
Advertisement
